President Donald Trump previously reported he earned capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc., the manufacturers of two of the medicines he’s taken as part of his COVID-19 treatment plan.
According to a 2017 financial disclosure form filed with the U.S. Office of Government Ethics in June 2017, Trump had a capital gain of $50,001 to $100,000 for Regeneron Pharmaceuticals and $100,001 to $1 million for Gilead Sciences Inc. The form notes the information was of April 15, 2017. Continue reading “Trump COVID-19 treatment: President had stakes in Regeneron and Gilead, makers of antibody cocktail, Remdesivir”